A CRA expert provided input to the Canadian Competition Bureau in its evaluation of the proposed merger of two branded pharmaceutical manufacturers. CRA’s team considered the ability and incentive of the merging parties to increase the price of a branded pharmaceutical following the merger. Aspects of this consideration included setting out the features of list and net pricing of branded drugs in the Canadian pharmaceutical marketplace, and the various constraints and factors that bear on those prices.
Comments on the effect of algorithms and artificial intelligence on the likelihood of coordinated effects as described in Guideline 3 of the draft Merger Guidelines
In this note, we discuss how the Antitrust Division of the Department of Justice and the Federal Trade Commission (collectively, the Agencies) view the effect...